Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide
3-kinase (p110α). In preclinical studies, it demonstrated strong activity against PI3K p110α
in vitro and in vivo, and inhibited tumor cell growth. The first-in-human trial is conducted
to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the
pharmacokinetics, safety and preliminary anti-tumor activity of HS-10352 at single dose and
multiple doses.